ACRS News and Press, Aclaris Therapeutics Inc. From 10/24/19

If approved, A-101 45% Topical Solution would be the first FDA-approved prescription treatment for common warts Highly statistically significant results for the primary efficacy endpoint Highly statistically significant results for all secondary efficacy endpoints Management to host...

TrovaGene (NASDAQ: TROV ) +56%  on positive response to treatment in phase 1b/2 trial of onvansertib in patients with KRAS-mutated metastatic colorectal cancer. More news on: TrovaGene, Inc., Biogen Inc., Stamps.com Inc., Stocks on the move, Read more ...

Viveve Medical (NASDAQ: VIVE ) +109%  on robust volume on no particular news. More news on: Viveve Medical, Inc., Achillion Pharmaceuticals, Inc., Ideal Power Inc., Stocks on the move, Read more ...

On the good news front in today's series, Stealth BioTherapeutics ( MITO ) and Alexion Pharmaceuticals ( ALXN ) have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Elamipretide, an inner mitochondrial membrane-targeting therapeutic, is Stealth BioTherapeutics...

Gainers: Synthesis Energy Systems (NASDAQ: SES ) +81% . MOGU (NYSE: MOGU ) +20% . Purple Innovation (NASDAQ: PRPL ) +19% . Fastenal (NASDAQ: FAST ) +17% . Aerie Pharmaceuticals (NASDAQ: AERI ) +17% . Valaris (NYSE: VAL ) +16% . Mmtec (NASDAQ: MTC ) +15% . Aclaris Therapeutics (NASD...

Synthesis Energy Systems (NASDAQ: SES ) +88%  on acquiring Australian Future Energy in all-stock deal. More news on: Synthesis Energy Systems, Inc., Aclaris Therapeutics, Inc., The Royal Bank of Scotland Group plc, Stocks on the move, Read more ...

Following through on its previously announced strategy to focus its resources on its immuno-inflammatory pipeline, Aclaris Therapeutics (NASDAQ: ACRS ) has agreed to sell global rights to rosacea topical cream RHOFADE (oxymetazoline) to EPI Health, LLC. More news on: Aclaris Therapeutics...

WAYNE, Pa., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it has divested RHOFADE® (oxymetazoline hydrochloride) cream, 1% (RHOFADE) and related intellectua...

Aclaris Therapeutics (NASDAQ: ACRS ) together with Allergan has filed a patent infringement lawsuit against Taro Pharmaceuticals (NYSE: TARO ) in Delaware court, related to an ANDA filed by Taro to market a generic version of RHOFADE (oxymetazoline hydrochloride) cream, 1%. More new...

WAYNE, Pa., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced today that the company, together with Allergan, Inc., has filed a patent infringement lawsuit in the United S...